Comment: Paediatric rhabdomyosarcoma survival extended with maintenance chemotherapy

Prof Richard Schilsky and Dr Gianni Bisogno comment on data, during a press conference at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, from a randomised phase III clinical trial of 6 months maintenance chemotherapy for children with the rare disease rhabdomyosarcoma.

For more detail, watch Dr Bisogno present the data in the press conference, watch Dr Bisogno speak with ecancer about the trial here, or read our news coverage here.
https://ecancer.org/conference..../1049-2018-asco-annu
https://ecancer.org/news/14117.php

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php